CHPA Statement on New Consumer Poll from The Asthma and Allergy Foundation of America
Clear Majority Opposes Prescription-Only PSE Requirements
WASHINGTON, March 1, 2013 /PRNewswire/ — The Consumer Healthcare Products Association (CHPA) released a statement today on the recent poll by the Asthma and Allergy Foundation of America (AAFA). The national poll, which was conducted by Harris Interactive and supported by a grant from CHPA, surveyed 2,000 Americans who have experienced asthma, allergy, cold, or flu symptoms in the past year.
“The 2013 survey confirmed what we have already been hearing in the states: that the large majority of cold, flu, and allergy sufferers oppose legislation that would require them to obtain a doctor’s prescription before buying safe and effective medicines containing pseudoephedrine,” said Scott Melville, president and CEO of the Consumer Healthcare Products Association.
The new survey included a thorough analysis of how patients receive treatment for their symptoms and found that respondents face a number of healthcare burdens, including difficulty making doctors appointments, pricey copays and missed time at work. Key findings from AAFA’s 2013 Survey include:
- Nearly two-thirds of respondents (62%) oppose legislation that would require a prescription for common cold and allergy medicines containing pseudoephedrine.
- A strong majority of respondents deal with allergy symptoms for more than two months per year (69.5 days on average)
- Only one-in-five patients can get in to see their doctor the same day, with nearly one quarter (22%) having to wait more than a week to get an appointment
- When including drive time, waiting-room time, and the visit itself, only one-in-five patients surveyed spend less than an hour when visiting the doctor, with nearly one-third (30%) requiring two or more hours per visit; one-in-ten (9%) require three or more hours per visit
“In addition to the overwhelming majority of respondents who are concerned about the burdens associated with a prescription mandate, the survey found that many patients are already frustrated by having to wait multiple days to see their doctor, make costly copayments and deal with a shortage of family doctors,” Melville continued. “Without question, these many burdens would be exacerbated by a prescription requirement. With these new findings in mind, CHPA will continue to work with AAFA to make sure lawmakers consider the needs of patients when crafting legislative solutions to the meth problem.”
Editor’s note: For more information about the survey, visit AAFA’s website at www.aafa.org/pse.
CHPA is the 132-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.
SOURCE Consumer Healthcare Products Association